home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

51.53 +0.02 (+0.04%)

Official Closing Price Updated: 4:10 PM EDT, Aug 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

45 46 Next >

Can Pfizer Beat GSK and Moderna in This $10 Billion Market? ↗

April 13, 2023

There's such a big need in preventing RSV that multiple companies should be big winners.

Via The Motley Fool

Why Shares of Adaptimmune Therapeutics Jumped Tuesday ↗

April 11, 2023

The company bulks up its pipeline by regaining the rights to two of its clinical programs.

Via The Motley Fool

Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments ↗

April 11, 2023

The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a...

Via Benzinga

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

April 11, 2023

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...

Via Newsfile

Back from the Dead, IBM’s Watson AI is Alive and Re-Emerging

April 10, 2023

While artificial intelligence (AI) seems to have come around full circle in 2023 as ChatGPT finally lit the fuse for full-blown mainstream adoption, Internat

Via MarketBeat

Topics Artificial Intelligence

This House of Representative Just Sold Up To $100K In GSK Stock ↗

April 05, 2023

Via Benzinga

GSK Bets On Scynexis' FDA-Approved Antifungal Drug For Over $500M In Bio Bucks ↗

March 30, 2023

Via Benzinga

2 Top Biotech Stocks to Buy in April ↗

April 04, 2023

Right now you can pick up these stocks on the dip.

Via The Motley Fool

Could This Move by Johnson & Johnson Equal Billions for Moderna? ↗

April 02, 2023

An RSV vaccine could be a driver of blockbuster revenue.

Via The Motley Fool

Texas Judge Obstructs Affordable Act Coverage Mandate For Some Cancer Screenings, Prophylaxis ↗

March 31, 2023

A Texas federal judge reportedly blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP),...

Via Benzinga

Stage Set For Generics As Biden Admin Asks Supreme Court To Hear Skinny Labels Case Between GSK, Teva ↗

March 31, 2023

Via Benzinga

SCYNEXIS (NASDAQ: SCYX) Enters Into Exclusive Agreement with GSK (NYSE: GSK) to Continue Commercializing Brexafemme to Treat Fungal Infections

March 30, 2023

SCYNEXIS, Inc. (NASDAQ: SCYX) operates as a biotechnology company, which is focused on the research and development of novel solutions

Via Spotlight Growth

GSK Stock Skids On Judge's New Ruling As Zantac Trial Looms ↗

March 24, 2023

A trial this summer will examine one Zantac user's cancer.

Via Investor's Business Daily

This Is What Whales Are Betting On GSK ↗

March 23, 2023

Via Benzinga

Daily Stock Analysis: GSK ↗

March 17, 2023

By my dogcatcher ideal, this is a proper time to buy GSK shares, based on their dividends for 2023.

Via Talk Markets

Why Is Scynexis (SCYX) Stock Up 69% Today? ↗

March 30, 2023

Scynexis (SCYX) stock is taking off on Tuesday as investors react to news of an exclusive license agreement for Brexafemme.

Via InvestorPlace

Viatris Among Three Companies Licensed To Make GSK/Pfizer-Backed Long Acting HIV Prevention Drug ↗

March 30, 2023

Via Benzinga

Johnson & Johnson Pulls Plug On Large Late-Stage Study Of RSV Vaccine Candidate; GSK, Pfizer Shots Are Under FDA Review ↗

March 29, 2023

Via Benzinga

J&J Drops Out Of A Key Race, Leaving Pfizer, GSK, Moderna To Duke It Out ↗

March 29, 2023

The company says it's refocusing its portfolio to focus on transformational medicines.

Via Investor's Business Daily

GSK Unveils Detailed Phase 3 Data For Jemperli In Frontline Endometrial Cancer Patients ↗

March 28, 2023

Via Benzinga

Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

March 27, 2023

Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.

Via MarketBeat

How Is The Market Feeling About GSK? ↗

March 15, 2023

Via Benzinga

Recent Stock Purchases For March 2023 ↗

March 25, 2023

As readers may know by now, I make stock purchases every single month, no matter what is going on in the world. This month, I went heavier than I normally do, deploying over $3,000. Let's take a look.

Via Talk Markets

Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information ↗

March 21, 2023

Via Benzinga

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗

March 20, 2023

Reuters

Via Benzinga

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗

March 20, 2023

Via Benzinga

3 Pharma Stocks That Could Benefit from Global Healthcare Trends ↗

March 17, 2023

The best pharma stocks to buy are those that are poised to be greatly boosted by drugs that are well-positioned to become blockbusters.

Via InvestorPlace

Better RSV Vaccine Stock: Pfizer, GSK, or Moderna? ↗

March 17, 2023

An approved RSV vaccine could be the next big thing for these companies.

Via The Motley Fool

GSK's Chief Scientist Says R&D Focus More On Infectious Disease, HIV Amid Patent Expiration, Dwindling Sales ↗

March 15, 2023

GSK Plc's (NYSE: GSK) top scientist, Tony Wood, who took the helm of R&D last August, says the R&D department is now delivering results. Wood said he is de-emphasizing R&D in oncology and that the R&D...

Via Benzinga

GSK and Earvin “Magic” Johnson Partner to Raise Awareness of Risk of RSV in Older Adults

March 14, 2023

From GSK plc

Via Business Wire

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com